inp.polri.go.id - Jakarta. The World Health Organization (WHO) and the Food and Drug Supervisory Agency (BPOM) have approved the use of the monkeypox vaccine or Mpox in Indonesia. This means that the Mpox vaccine can be given in health emergency situations.

"The Mpox vaccine has received Emergency Use Listing (EUL) from WHO and Emergency Use Authorization (EUA) from BPOM. This means that this vaccine can be used in emergency conditions," said the Spokesperson for the Ministry of Health, Mohammad Syahril in an official statement on Thursday (9/12/2024).

Spokesperson Syahril's statement responded to the narrative claiming that the prepared Mpox vaccine was an experimental vaccine. The claim was accompanied by an invitation for the public to reject the Mpox vaccine.

"In fact, the claim is wrong," said Spokesperson Syahril. "In the implementation of vaccination, the National Commission for Post-Immunization Adverse Events (Komnas KIPI) also monitors safety and ensures the benefits of vaccination," continued Spokesperson Syahril.

As an effort to prevent transmission of the Mpox virus, BPOM with Komnas KIPI continues to monitor the use of the Mpox vaccine. This is done to ensure its safety and benefits.

The Mpox vaccine currently used in Indonesia is the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) type. This vaccine is a smallpox derivative vaccine, the third generation which is non-replicating.

The inoculation of Mpox vaccination with MVA-BN has been carried out since 2023. This was done after a confirmed case of Mpox or Monkeypox was found in Indonesia. 

(ad/ndt/pr/nm)